In particular, oncogenic signal changes in persistent EGFR-mutant tumor cells affected by the immune microenvironment immediately after EGFR-TKI treatment are essential for studying the development of resistance mechanisms of EGFR-TKIs, but cannot have been studied with human clinical samples, especially before developing clinical progression. The gene discussed is EGFR; the disease is neoplasm.